Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LB101 |
Trade Name | |
Synonyms | |
Drug Descriptions |
LB101 is a conditionally activated bispecific antibody targeting both CD47 and PD-L1 (CD274), which may promote antibody-dependent cellular phagocytosis in PD-L1 (CD274)-positive tumor microenvironment (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2562). |
DrugClasses | CD47 Antibody 31 PD-L1/PD-1 antibody 121 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
LB101 | LB101 | 0 | 1 |